$2.26T
Total marketcap
$127.71B
Total volume
BTC 50.00%     ETH 15.48%
Dominance

Broncus Holding Corporation 2216.HK Stock

0.58 HKD {{ price }} -3.333340% {{change_pct}}%
COUNTRY
Hong Kong
Exchange
HKSE
Market Cap
283.4M HKD
LOW - HIGH [24H]
0.51 - 0.6 HKD
VOLUME [24H]
1.5K HKD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.47 HKD

Broncus Holding Corporation Price Chart

Broncus Holding Corporation 2216.HK Financial and Trading Overview

Broncus Holding Corporation stock price 0.58 HKD
Previous Close 1.2 HKD
Open 1.18 HKD
Bid 1.19 HKD x N/A
Ask 1.2 HKD x N/A
Day's Range 1.18 - 1.23 HKD
52 Week Range 1.08 - 3.06 HKD
Volume 655K HKD
Avg. Volume 489.71K HKD
Market Cap 585.96M HKD
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -0.47 HKD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 4.07 HKD

2216.HK Valuation Measures

Enterprise Value 445.48M HKD
Trailing P/E N/A
Forward P/E -4.8
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 62.24957
Price/Book (mrq) 2.962963
Enterprise Value/Revenue 47.326
Enterprise Value/EBITDA -14.569

Trading Information

Broncus Holding Corporation Stock Price History

Beta (5Y Monthly) N/A
52-Week Change -49.36%
S&P500 52-Week Change 20.43%
52 Week High 3.06 HKD
52 Week Low 1.08 HKD
50-Day Moving Average 1.59 HKD
200-Day Moving Average 1.97 HKD

2216.HK Share Statistics

Avg. Volume (3 month) 489.71K HKD
Avg. Daily Volume (10-Days) 456.4K HKD
Shares Outstanding 488.3M
Float 298.4M
Short Ratio N/A
% Held by Insiders 12.24%
% Held by Institutions 57.96%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -297.84%
Operating Margin (ttm) -347.47%
Gross Margin 77.71%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -8.61%
Return on Equity (ttm) -12.30%

Income Statement

Revenue (ttm) 9.41M HKD
Revenue Per Share (ttm) 0.02 HKD
Quarterly Revenue Growth (yoy) -22.90%
Gross Profit (ttm) 7.32M HKD
EBITDA -30577000 HKD
Net Income Avi to Common (ttm) -28036000 HKD
Diluted EPS (ttm) -0.48
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 188.24M HKD
Total Cash Per Share (mrq) 0.36 HKD
Total Debt (mrq) 1.47M HKD
Total Debt/Equity (mrq) 0.69 HKD
Current Ratio (mrq) 27.351
Book Value Per Share (mrq) 0.405

Cash Flow Statement

Operating Cash Flow (ttm) -30954000 HKD
Levered Free Cash Flow (ttm) -22320750 HKD

Profile of Broncus Holding Corporation

Country Hong Kong
State N/A
City Hangzhou
Address Building 8
ZIP N/A
Phone N/A
Website https://www.broncus.com
Industry Medical Devices
Sector(s) Healthcare
Full Time Employees 376

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker that is used to mark the location of the lung nodule to achieve precise positioning during surgical pneumonectomy. In addition, the company provides diagnosis products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. The company was incorporated in 2012 and is headquartered in Hangzhou, China.

Q&A For Broncus Holding Corporation Stock

What is a current 2216.HK stock price?

Broncus Holding Corporation 2216.HK stock price today per share is 0.58 HKD.

How to purchase Broncus Holding Corporation stock?

You can buy 2216.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Broncus Holding Corporation?

The stock symbol or ticker of Broncus Holding Corporation is 2216.HK.

Which industry does the Broncus Holding Corporation company belong to?

The Broncus Holding Corporation industry is Medical Devices.

How many shares does Broncus Holding Corporation have in circulation?

The max supply of Broncus Holding Corporation shares is 488.62M.

What is Broncus Holding Corporation Price to Earnings Ratio (PE Ratio)?

Broncus Holding Corporation PE Ratio is now.

What was Broncus Holding Corporation earnings per share over the trailing 12 months (TTM)?

Broncus Holding Corporation EPS is -0.47 HKD over the trailing 12 months.

Which sector does the Broncus Holding Corporation company belong to?

The Broncus Holding Corporation sector is Healthcare.